Boost Selectivity, Overcome Resistance & Leverage Combination Strategies for Safe & Efficacious Hippo Pathway Targeted Therapies Towards Clinical Success in Oncology, Regenerative Medicine & Beyond
November 20-21, 2024 | Virtual Summit
Welcome to the 3rd Hippo Pathway Targeted Drug Development Summit
Igniting Novel YAP, TAZ & TEAD Modulators Towards Clinical Validation
The field of Hippo Pathway targeted drugs is seeing a surge of activity, with new clinical data being generated everyday and novel combinations being tested. The 3rd Hippo Pathway Targeted Drug Development Summit has been built alongside industry experts from the likes of Vivace Therapeutics, Orion Pharma, Insilico Medicine and more to return as the premier event for Hippo industry leaders focusing on developing innovative, safe, and effective therapies in oncology, fibrosis, and beyond.
Join over 20 global Hippo experts as we advance YAP, TAZ, and TEAD modulators towards clinical success – right from the comfort of your screen! This is your virtual hub to meet 80+ Hippo experts from across the globe gathering for data-led presentations, deep-diving panels, and interactive roundtables to advance the Hippo industry forward.
Our World-Class Speaker Faculty for 2024 Includes:
Srinivas Vinod Saladi
Assistant Professor of Cell and Cancer Biology (Co-Founder, Stealth mode start-up)
University of Toledo, College of Medicine and Life Sciences
Previously Attending Companies Include:
What Previous Attendees Had to Say:
“The Hippo Summit is an ideal venue to exchange ideas, learn about cutting edge research, and engage with top researchers in the field.” – Postdoctoral Researcher, Genentech
“This meeting provides an update on state-of-the-art therapeutic strategies that target components of the Hippo pathway. This is our primary research theme; therefore, attending this meeting is crucial for apprising current developments and drawing inspiration. Additionally, meetings, such as this, foster collaboration, which is crucial for advancing the field.” – Assistant Professor, Cleveland Clinic
“Participating in the 3rd Hippo Pathway Targeted Drug Development Summit will foster scientific exchange around new opportunities, advancements and challenges of Targeting the Hippo signaling pathway. The possibility to hear the latest findings from key players in the field will foster the next round of investigation at all levels: from early drug discovery to drug development to the clinic.” – Head of Research & Discovery, QUANTRO Therapeutics GmbH
Other events in the Small Molecules & TPD World Series
